Fifteen years of gene therapy based on chimeric antigen receptors: Are we nearly there yet?

Gianpietro Dotti, Barbara Savoldo, Malcolm Brenner

Research output: Contribution to journalReview article

69 Scopus citations

Abstract

T-body or chimeric antigen receptor (CAR) technology, which combines the specificity of an antibody with the homing, tissue penetration, and target cell destruction of T cells, was first described in 1993. After many years of unmet promise, significant improvements in gene transfer, including the development of efficient retroviral vectors for transduction of human T cells, and better understanding of immunological pathways and immune cell interactions, are allowing this technology to reach a critical phase of evaluation, in which we will learn whether the approach can truly meet expectations. In this review we summarize the concept of CAR-based immunotherapy, describe the steps accomplished, and outline the future progress we need to make if this approach is truly to improve cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)1229-1239
Number of pages11
JournalHuman Gene Therapy
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2009

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Fifteen years of gene therapy based on chimeric antigen receptors: Are we nearly there yet?'. Together they form a unique fingerprint.

Cite this